Vaccines

The move comes just in time for the holiday travel season.

The administration is also reportedly planning on purchasing millions of doses of the company’s antiviral pill.

The company is asking the FDA to make the additional shots available to anyone 18 years old or older.

Wrangling over the requirement continues in the courts.

After a panel federal judges put a temporary halt on the mandate, the U.S. Surgeon General says the administration is ready to fight for the requirement.

The regulation would affect more than 17 million healthcare workers.

The agency moved quickly to approve the smaller shots.

The vaccine is just awaiting a recommendation from the CDC before they can be rolled out.

A previous analysis found the vaccine was 90.7 percent effective against severe COVID-19.

The FDA is expected to act on an EUA application for the smaller doses next week.

The administration sees pediatricians and primary care physicians taking the lead in the push.

The agency is expected to decide on that as well as Moderna and Johnson and Johnson boosters this week.

The advisory panel is also scheduled to discuss Merck antiviral pill late next month.

A recommendation is expected on whether the shot should be authorized.

The Biden administration says that vaccination mandates are not leading to the mass resignations in health that some expected.

The drug has proven effective in patients between 5 and 11 years old, according to Pfizer.

The leading causes of the bump in COVID-19 vaccination are tied to the impact of the disease.

CDC Director Walensky overrode an agency panel to recommend the shots for healthcare workers.

The agency did not recommend the additional shots for the general public.

A study shows an additional dose of the vaccine gives the patient 94 percent protection against symptomatic COVID-19 in the U.S.

The Vaccines and Related Biological Products Advisory Committee voted against recommending the extra shots for the general public.

The organization says the government’s requirements are appropriate.

The Vaccines and Related Biological Products Advisory Committee will meet Sept. 17.

August saw a rise in COVID-19 vaccination rates as people seek to avoid the more transmissible Delta variant.

While the vaccine rollout has snagged, the effort has already saved thousands.

Trials have shown a booster of the single-dose vaccine produces a robust increase in spike-binding antibodies.

The organization says the medical community should wait for results from the clinical trials for vaccinating patients under 12.

The Biden administration will make the additional doses of two COVID-19 vaccines available to combat the Delta variant.

The organization wants the current emergency use authorization to be expanded to include patients under 12.

The rollout of the boosters is expected to follow a similar track to that used in the first round of immunizations.